Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence

Pediatrics

Volumn 126, Issue 4, 2010, Pages

  Vesikari, Timo ^a   Karvonen, Aino ^a   Tilman, Sandrine ^b   Borkowski, Astrid ^c   Montomoli, Emanuele ^d   Banzhoff, Angelika ^b   Clemens, Ralf ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b Clinical Research and Development   (United States)

^c Global Clinical Research and Development   (Germany)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

Adjuvanted influenza vaccine; Adolescents; Avian influenza; Children; H5N1 influenza vaccine; Prepandemic influenza vaccine; Toddlers

Indexed keywords

AFLUNOV; INFLUENZA VACCINE; INFLUENZA VIRUS A H5N1 VACCINE; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; MF59 OIL EMULSION; POLYSORBATE; SQUALENE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GROUPS BY AGE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE TENDERNESS; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PATHOLOGICAL CRYING; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTECTION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEROCONVERSION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; TODDLER; VACCINATION REACTION; VIRUS NEUTRALIZATION; IMMUNIZATION; IMMUNOLOGY; INFLUENZA VIRUS A H5N1; INFLUENZA, HUMAN;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION; INFANT; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; POLYSORBATES; SQUALENE; VACCINES, INACTIVATED;

EID: 77957701029     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2009-2628     Document Type: Article

References (38)

1. World Health Organization. Avian influenza. Available at: http://www.who.int/csr/disease/avian-influenza/en. Accessed July 27, 2010
2. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO, 23 April 2009. Available at: http://www.who.int/csr/disease/avian-influenza/country/cases-table-2009-04-23/ en/index.html. Accessed May 4, 2009
3. World Health Organization. Avian Influenza: Assessing the Pandemic Threat. Geneva, Switzerland: World Health Organization; 2005. Publication WHO/CDS/2005.29. Available at: http://www.who.int/csr/disease/influenza/H5N1- 9reduit.pdf. Accessed July 27, 2010
4. Uyeki TM. Global epidemiology of human infections with highly pathogenic avian influenza A (H5N1) viruses. Respirology. 2008;13(suppl 1):S2-S9 (Pubitemid 351661387)
5. Melidou A, Gioula G, Exindari M, Chatzidimitriou D, Diza-Mataftsi E. Influenza A(H5N1): an overview of the current situation. Eurosurveillance. 2009;14(20). Availableat:http://www.eurosurveillance.org/ViewArticle.aspx? ArticleId=19216
6. World Health Organization. WHO Strategic Action Plan for Pandemic Influenza 2006-2007. Geneva, Switzerland: World Health Organization; 2006. Publication WHO/CDS/EPR/GIP/2006.2. Available at: http://www.who.int/csr/ resources/publications/influenza/WHO-CDS-EPR-GIP-2006-2c.pdf. Accessed July 27, 2010
7. Sambhara S, Poland GA. Breaking the immunogenicity barrier of bird flu vaccines. Lancet. 2007;370(9587):544-545
8. Stephenson I, Gust I, Kieny MP, Pervikov Y. Development and evaluation of pandemic influenza vaccines. Lancet Infect Dis. 2006;6(2):71-72 (Pubitemid 43138904)
9. Subbarao K, Murphy BR, Fauci S. Development of effective vaccines against pandemic influenza. Immunity. 2006;24(1):5-9
10. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006;354(13):1343-1351
11. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines. 2007;6(5):699-710
12. Puig BJ, González VD. MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations. Expert Rev Vaccines. 2007;6(5):659-665
13. Gasparini R, Pozzi T, Montomoli E, et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol. 2001;17(2):135-140 (Pubitemid 32900039)
14. De Donato S, Granoff D, Minutello M, et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine. 1999;17(23-24):3094- 3101
15. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology. 2003;49(3):177-184
16. de Roux A, Marx A, Burkhardt O, et al. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine. 2006;24(10):1537-1542 (Pubitemid 43238228)
17. Iorio AM, Francisci D, Camilloni B, et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine. 2003;21(25-26):3629-3637 (Pubitemid 37338187)
18. Vesikari T, Pellegrini M, Karvonen A, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J. 2009;28(7):563-571
19. American Academy of Pediatrics, Committee on Infectious Diseases. Prevention of influenza: recommendations for influenza immunization of children, 2008-2009. Pediatrics. 2008;122(5):1135-1141
20. Weycker D, Edelsberg J, Halloran ME, et al. Population-wide benefits of routine vaccination of children against influenza. Vaccine. 2005;23(10):1284- 1293
21. US Department of Health and Human Services. Draft Guidance on Allocating and Targeting Pandemic Influenza Vaccine 2007. Washington, DC: US Department of Health and Human Services; 2007. Available at: www.flu.gov/individualfamily/ vaccination/allocatinguidance.pdf. Accessed July 27, 2010
22. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature. 2006;442(7101):448-452
23. Galli G, Hancock K, Hoschler K, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A. 2009;106(19):7962-7967
24. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet. 2001;357(9272):1937-1943
25. Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis. 2004;4(8):499-509 (Pubitemid 39077920)
26. Schild GC, Pereira MS, Chakraverty P. Single-radial-hemolysis: a new method for the assay of antibody to influenza haemagglutinin: applications for diagnosis and seroepidemiologic surveillance of influenza. Bull World Health Organ. 1975;52(1):43-50
27. Bresson J-L, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet. 2006;367(9523):1657-1664
28. Nolan T, Richmond PC, Formica NT, et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine. 2008;26(50):6383-6391
29. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007;370(9587):580-589
30. Banzhoff A, Gasparini R, Laghi-Pasini F, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One. 2009;4(2):e4384
31. Stephenson I, Nicholson KG, Hoschler K, et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med. 2008;359(15):1631-1633
32. European Committee for Medicinal Products for Human Use. Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. Brussels, Belgium: European Commission on Enterprise and Industry; 1997. Publication CPMP/BWP/214/96. Available at: www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003945.pdf. Accessed July 27, 2010
33. Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines. 2003;2(2):197-203
34. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001;19(17-19):2673-2680 (Pubitemid 32234288)
35. Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD®) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine. 2009;27(45):6291-6295
36. Banzhoff A, Lattanzi M, Clemens R. Safety data from clinical trials and pharmacovigilance of mass vaccination with MF59®-adjuvanted H1N1 influenza vaccines. Presented at the 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 4-8, 2010; Nice, France
37. Black S, Vesikari T, Della Cioppa G, Pellegrini M, Nicolay U. Safety of MF59®-adjuvanted seasonal and pandemic influenza vaccines in pediatric populations and pregnant women. Presented at the 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 4-8, 2010; Nice, France
38. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis. 2008;8(10):650-658